A.S. Zandvliet(1,2), A.D.R. Huitema(1,2), M.E. de Jonge(1,2), R. den Hoed(3), R.W. Sparidans(3), V.M. Hendriks(4,7), W. van den Brink(5,7), J.M. van Ree(6,7), J.H. Beijnen(1,2,3) Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine
|
S. Gisbert, L. Aarons and M. Rowland. Different approaches to the development of a WBPBPK model with a series of barbiturates using population modelling
|
K. Ogungbenro, G. Graham and L. Aarons The Design of Population Pharmacokinetic Studies: Sample Size Determination
|
T. Lehr (1), C. Tillmann (2), A. Staab (2), D. Trommeshauser (2), H.G. Schaefer (2), C. Kloft (1) Clock time as a control variable for gall bladder emptying in an enterohepatic circulation model
|
E.Y.L. Blair(1), D.R. Mould(2), S.J. Clarke(3), L.P. Rivory(4), A.J. McLachlan(1) Pharmacokinetic-Pharmacodynamic Modelling of Raltitrexed in Patients with Advanced Solid Tumours
|
Holger Kraiczi (1), Marianne Frisén (2) Effect of Uncertainty About Population Parameters on Pharmacodynamics-Based Prediction of Clinical Trial Power - A Method for Sensitivity Analysis
|
B. Ploeger(2), N. Houwing(1), A. Bom(3), M.P. van Iersel(1), D. Zollinger(1), M. Danhof(2) The reversal of rocuronium-induced neuromuscular block by the cyclodextrin ORG25969: model development and validation
|
Willem de Winter (1), Teun Post (1), Joost DeJongh (1,2), Richard Urquhardt(3), Ian Moules (3), David Eckland (3) and Meindert Danhof (1,2) A Mechanistic Disease Progression Model for Type 2 Diabetes Mellitus and Pioglitazone Treatment Effects
|
Michael K. Smith(1), Scott Marshall(2), John Huggins(2). A Bayesian design and analysis for dose-response using informative prior information
|
E Lamont (1), AH Thomson (2,3), M Dawber (2), L Semple (4), E Bell (4), RA Seaton (4) Population Pharmacokinetics of Teicoplanin in Outpatient Home Parenteral Antibiotic Therapy (OHPAT)
|
Matthew L. Zierhut(1), Mark C. Peterson(2), Marc R. Gastonguay(3), Steven W. Martin(2), Paolo Vicini(1), Pirow J. Bekker(2), Donna Holloway(2), Philip T. Leese(4) Development and Evaluation of a Population PK/PD Model for Fc-OPG in Healthy Postmenopausal Women
|
Aris Dokoumetzidis and Leon Aarons Propagation of population pharmacokinetic information using a Bayesian approach
|
M. Pfister, S. Krishnaswami, S. Rohatagi Characterization of Cortisol Circadian Rhythm and Lack of Cortisol Suppression by a New Corticosteroid, Ciclesonide
|
V. Piotrovsky(1), G. Kopia(2), G.W. Vetrovec(3), D. Rizik(4), David Snead(2) Population pharmacokinetic analysis of concentration data after implantation of sirolimus-eluting Bx Velocity stent in patients
|
K.H. Liesenfeld, EU. Gräfe-Mody, A. Staab, H.G. Schaefer Population pharmacokinetics of a new anticoagulant drug in clinical development
|
Jean-Eric Charoin(1), Philippe Jacqmin(2), Ludger Banken(3), Sian Lennon(4) and Karin Jorga(1) Population Pharmacokinetic Analysis of Trastuzumab (Herceptin) following Long-Term Administration Using Different Regimens.
|
JS Barrett (1,4), A Zuppa (1,3), M Schreiner (5) and PC Adamson (1, 2, 4) Esmolol Population Pharmacokinetics in Critically-ill, Pediatric Patients
|
Jakob Ribbing and E. Niclas Jonsson Learning about Covariate Relations in the Patient Population Based on Data from Multiple Studies – Consequences of Different Approaches
|
L.E. Friberg, C. Dansirikul and S.B. Duffull Simultaneous fit of competing models as a model discrimination tool in Bayesian analysis
|
Hugo Maas, Meindert Danhof, Oscar Della Pasqua Comparison of sumatriptan and naratriptan using a markov model approach
|
F. Fiorentini (2), M. Simeoni (1), I. Poggesi (2), G. Westerberg (2), M. Rocchetti (2) An example of application of the population approach to toxicological studies.
|
Annick Rousseau, Aurélie Prémaud, Pierre Marquet Modeling the complex pharmacokinetic profiles of cyclosporin and of mycophenolate observed in the early post-transplantation period.
|
Vermeulen, An; Piotrovsky, Vladimir and De Ridder, Filip Modeling the occurrence of orthostasis using a longitudinal logistic regression model
|
B. Mc Hugh, N. Frey Population PK and PK/PD Analyses of an Enzyme Inhibitor in Healthy Volunteers
|
C. Lia Liefaard (1), Bart A. Ploeger (1,2), Carla F.M. Molthoff (3), Ronald Boellaard (3), Adriaan A. Lammertsma (3), Meindert Danhof (1,2), Rob A. Voskuyl (1,4) Application of Population Pharmacokinetic Analysis for Quantification of in vivo Binding Properties in the Rat Brain by Positron Emission Tomography
|
Daniel M. Jonker (1), Derek Leishman (2), Rob Wallis (2), Peter E. Milligan (2) and E. Niclas Jonsson Development and validation of a mechanism-based PK/PD model for the in vitro-in vivo prediction of QT prolongation by dofetilide
|
Simeoni M (1), Poggesi I (2), Germani M(2), De Nicolao G(1), Rocchetti M(2). Population modeling of tumor growth inhibition in vivo: application to anticancer drug development
|
Xuejun Chen, Al Corey, Suresh Mallikaarjun, Steve Bramer Population Pharmacodynamic Analysis of QTc Prolongation vs. Plasma Concentration
|
Michael G Dodds(1), Paolo Vicini(1), Jennifer E Visich(2) and Mark Rogge(2) A Population PK Model for Recombinant Factor XIII in Congenitally Deficient Subjects
|
F. Hourcade-Potelleret, C. Weber, B. Fotteler and N. Frey Population PK Analysis in Sparse Data and Flexible Sampling Time Conditions
|
Emmanuelle Comets, France Mentré and François Gimenez Cerebral uptake of mefloquine enantiomers with and without theP-gp inhibitor elacridar (GF1210918) in mice
|
K.C. Carlsson (1), N.O. Hoem (2), T. Glauser (3), A. A. Vinks (4). Can clinically useful population PK models for carbamazepine in pediatric epilepsy patients be developed based on routine therapeutic drug monitoring (TDM) data?
|
Sandra A.G. Visser (1), Björn Sällström (1), Tomas Forsberg (2), Svante B. Ross (3), Lambertus A. Peletier (4) and Johan Gabrielsson (1) Modeling of drug- and system-related changes in body temperature: application to drug-induced hypothermia, long-lasting tolerance development and diurnal variation in body temperature
|
E. Tousset (1), C. Reners (1) & B. Vrijens (1-2) Identifying and minimizing major sources of variability in population pharmacokinetic studies
|
Isabelle Pouliquen, Lutz Harnisch A Population PK/PD Model for Cortisol Suppression
|
K. Brendel (1), E. Comets (1), C. Laveille (2), R. Jochemsen (2), F. Mentré (1) Comparison of several prediction errors on concentrations for model evaluation
|
Michael G Dodds(1), Andrew C. Hooker(1) and Paolo Vicini(1) Robust Population Pharmacokinetic Experiment Design
|
Pieter Janssen(1,2), Nicolaas H. Prins(2), Pieter J. Peeters(2), Klaas P. Zuideveld(3) and Romain A. Lefebvre(1) Quantification of 5-HT7 receptor efficacy distribution throughout the canine stomach using the operational model of agonism.
|
N.O. Hoem (1), P. Beringer (2) A non-parametric (NPAG) population PK model of orally and intravenously administered linezolid.
|
Andrew Hooker, Michael G. Dodds, Paolo Vicini Evaluating the predictive power of the Fisher information matrix in population optimal experimental design
|
Sylvie Retout, Emmanuelle Comets and France Mentré Comparison between the Fedorov-Wynn algorithm and the Simplex algorithm for population designs optimisation using a model of the HIV viral load decrease
|
M Valle, M Yritia, R Antonijoan, G Urbano, MR Ballester, MJ Barbanoj Population pharmacokinetic/pharmacodynamic modeling of the possible tolerance development after a single oral dose of different BZD-GABAa agonists.
|
Maria C. Kjellsson, Mats O. Karlsson Fitting Proportional Odds model to Ordered Categorical Data using the NLMIXED Procedure
|
O. Sayar(1), L. Bueno(1), M.J. Garrido(1), F. Rombout(2), I.F. Trocóniz(1) Comparison of different models to describe simultaneously the kinetics of parent drug and metabolites after oral administration.
|
Niels Rode Kristensen A Deconvolution Method for Linear and Nonlinear Systems based on Stochastic Differential Equations
|
Dymphy Huntjens (1), Anne Chain (1), David Spalding (2), Meindert Danhof (1) and Oscar Della Pasqua(1,3) Population semi-parametric modelling of the pharmacokinetics of rofecoxib in rats
|
Poggesi I (1), Simeoni M (2), Germani M(1), De Nicolao G(2), Rocchetti M(1) Population modeling of tumor growth in untreated xenografted mice
|
C Segura1, E Bandrés2, I F Trocóniz1, J García-Foncillas2,O Sayar1, C Dios-Vieitez1, M J Renedo1, M J Garrido1 Modelling of the effect of Topotecan on B cell subsets in tumor bearing rats.
|
Lars Lindbom, Pontus Pihlgren and E. Niclas Jonsson PsN Toolkit, a collection of computer intensive methods for population PK/PD
|
Justin J Wilkins (1), Grant Langdon (1), Helen McIlleron (1), Goonaseelan Pillai (2), Peter J Smith (1) and Ulrika SH Simonsson (3) A population pharmacokinetic-enzyme model for rifampicin autoinduction and bimodal absorption in pulmonary tuberculosis patients
|
CMJ Kirkpatrick(1), SB Duffull(1), ML Barclay(2), N Patton(3), GA Moore(4), MP Doogue( 1) Population pharmacokinetic analysis of high-dose oral busulphan for bone marrow transplant in adults and children
|
Willi Weber, Diether Rueppel, Heiner Speth Comparing efficacy of 10mg vs 20mg ARAVA in treatment of rheumatoid arthritis: A Population PK / PD Analysis
|
H. Silber (1), P. Stetina (1), B. McHugh (2), R. Gieschke (2), N. Frey (2), P. Vicini (3), U.S.H. Simonsson (1), M.O. Karlsson (1) A disease model for the regulation of the glucose-insulin system
|
R. V. Overgaard(1,2), E. N. Jonsson(3), C. W. Tornøe(4), H. Madsen(2) Non-Linear Mixed Effects Models with Stochastic Differential Equations - Implementation of an Estimation Algorithm
|
Marc Lavielle(1) and the Monolix research group(2) SAEM in MATLAB: an alternative to linearization
|
C. Ambery (1), L. Aarons (1) Population Pharmacokinetics and Response of ICL670 a Novel Oral Iron Chelator in Beta-Thalassaemia Patients
|
John C Lukas(1), Martina Samiotaki(2), Maria Kontou(2), Rosario Calvo(3), Panos Macheras(1), Tasos Zografidis(3), Georgios Kyriakides(4) The cytochrome P450 3AP1 variant genotype shows correlation with the true clearance in a renal transplant population
|